Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day
Clinical-stage biotech Windward Bio priced its IPO at $17 per share and closed its first trading day at $28.50 on Nasdaq.
Windward Bio, a clinical-stage biotechnology company backed by Qiming Venture Partners, made its public market debut on Nasdaq on November 13, 2026, under the ticker symbol WWB, the Shanghai-based firm announced.
The company priced its initial public offering at $17.00 per share. By the close of its first trading session, shares had climbed to $28.50, representing a gain of roughly 68 percent from the offering price — a strong opening-day performance by any measure in the current biotech IPO environment.
Read more Leverage Shares Launches 2x Long Anthropic ETF as ANT Debuts on Nasdaq →
Windward Bio focuses on immunology, a therapeutic area that has attracted sustained investor interest as drug developers pursue treatments targeting immune system dysfunction across a range of diseases. The company's listing adds to a pipeline of biotech firms seeking U.S. public market access through Nasdaq.
Qiming Venture Partners, a prominent venture capital firm with deep roots in China's technology and life sciences sectors, holds a portfolio stake in Windward Bio. The firm's backing lends the IPO additional credibility among institutional investors evaluating early-stage biotech risk.
The debut signals continued appetite for clinical-stage biotechnology offerings on U.S. exchanges, even as broader market conditions have been uneven for growth-oriented listings. Continue reading at All Financial Services & Investing.